BINI, C.; MARCELLUSI, A.; MENNINI, F. S.; RIPOLI, S.; FIORAVANTI, L.; PALY, V. F.; MOLINARI, A.; MORELLI, P.; KROTNEVA, S.; LI, S. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy. Global and Regional Health Technology Assessment, [S. l.], v. 11, n. 1, p. 248–257, 2024. DOI: 10.33393/grhta.2024.3167. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/3167. Acesso em: 22 jan. 2025.